The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Generic tenofovir disoproxil fumarate/emtricitabine the most frequently prescribed medication since 2021. (HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

The measure waives the need for a primary care physician’s prescription for HIV medications like PrEP and Doxy PEP.

The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...